在复发或难治性套细胞淋巴瘤中,利妥昔单抗、大剂量阿糖胞苷和地塞米松联合或不联合硼替佐米:欧洲套细胞淋巴瘤网络的一项随机、开放标签III期试验
该随机、开放标签、平行组III期试验纳入不适合自体干细胞移植或移植后复发的复发/难治性套细胞淋巴瘤患者128例,比较R-HAD联合硼替佐米与单纯R-HAD的疗效。联合硼替佐米组中位治疗失败时间12个月 vs 2.6个月(p=0.045,MIPI校正HR 0.69;95%CI 0.47-1.02),总缓解率63% vs 45%(p=0.049),完全缓解率42% vs 19%(p=0.0062)。
要点
- 联合硼替佐米组中位治疗失败时间12个月 vs 单纯R-HAD组2.6个月(p=0.045,MIPI校正HR 0.69;95%CI 0.47-1.02)。
- 联合硼替佐米组总缓解率63% vs 45%(p=0.049),完全缓解率42% vs 19%(p=0.0062)。
- 年龄>65岁亚组aHR 0.48(95%CI 0.29-0.79),无既往ASCT亚组aHR 0.52(95%CI 0.28-0.96)。
核心结论
- 硼替佐米联合化疗在复发/难治性套细胞淋巴瘤中可能有效,应进一步评估作为治疗选择,尤其在BTK抑制剂不是可选方案时。
研究设计与样本
- 随机、开放标签、平行组III期试验,计划入组175例,实际随机128例至R-HAD+B组(n=64)或R-HAD组(n=64)。
- 研究对象为不适合自体干细胞移植或移植后复发的复发/难治性套细胞淋巴瘤患者。
- 主要终点为治疗失败时间,次要终点包括缓解率、无进展生存、总生存和安全性。
- 试验注册号NCT01449344。
主要发现
- 中位治疗失败时间12个月 vs 2.6个月(p=0.045,MIPI校正HR 0.69;95%CI 0.47-1.02)。
- 总缓解率63% vs 45%(p=0.049),完全缓解率42% vs 19%(p=0.0062)。
- 年龄>65岁亚组aHR 0.48(95%CI 0.29-0.79),无既往ASCT亚组aHR 0.52(95%CI 0.28-0.96)。
- 毒性主要为血液学毒性,归因于化疗骨架;≥3级白细胞减少和淋巴细胞减少在R-HAD+B组更常见,两组严重感染无差异。
临床怎么用
- 作者认为硼替佐米联合化疗在复发/难治性套细胞淋巴瘤中可能有效,应进一步评估作为治疗选择,尤其在BTK抑制剂不是可选方案时。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The therapy of relapsed or refractory (r/r) mantle cell lymphoma (MCL) patients remains a major clinical challenge to date. We conducted a randomized, open-label, parallel-group phase-III trial hypothesizing superior efficacy of rituximab, high-dose cytarabine and dexamethasone with bortezomib (R-HAD + B) versus without (R-HAD) in r/r MCL ineligible for or relapsed after autologous stem cell transplant (ASCT). Primary endpoint was time to treatment failure (TTF), secondary endpoints included response rates, progression free survival, overall survival, and safety. In total, 128 of 175 planned patients were randomized to R-HAD + B (n = 64) or R-HAD (n = 64). Median TTF was 12 vs. 2.6 months (p = 0.045, MIPI-adjusted HR 0.69; 95%CI 0.47-1.02). Overall and complete response rates were 63 vs. 45% (p = 0.049) and 42 vs. 19% (p = 0.0062). A significant treatment effect was seen in the subgroup of patients >65 years (aHR 0.48, 0.29-0.79) and without previous ASCT (aHR 0.52, 0.28-0.96). Toxicity was mostly hematological and attributable to the chemotherapeutic backbone. Grade ≥3 leukocytopenia and lymphocytopenia were more common in R-HAD + B without differences in severe infections between both arms. Bortezomib in combination with chemotherapy can be effective in r/r MCL and should be evaluated further as a therapeutic option, especially if therapy with BTK inhibitors is not an option. Trial registration: NCT01449344.
引用
- Fischer L, Jiang L, Dürig J, et al. The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network. Leukemia. 2024. PMID: 38678093. doi:10.1038/s41375-024-02254-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。